Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015
  • USA - Français
  • USA - Deutsch
  • USA - English


News provided by

Johnson & Johnson

Jan 22, 2015, 06:06 ET

Share this article

Share toX

Share this article

Share toX

NEW BRUNSWICK, Nueva Jersey, 22 de enero de 2015 /PRNewswire/ -- El Dr. Paul Janssen Award for Biomedical Research abre hoy su llamada a nominaciones para 2015. Este prestigioso premio reconoce a las personas cuya investigación científica ha hecho, o tiene el potencial para hacer, contribuciones destacadas para la mejora de la salud humana. Las nominaciones se aceptarán hasta el 15 de marzo de 2015 a través de www.pauljanssenaward.com para su consideración por medio de un comité de selección independiente de prestigiosos científicos mundiales. Comenzando en 2015, el premio en efectivo otorgado al científico o grupo de científicos que reciban el premio se aumentará hasta los 200.000 dólares. Este aumento en el premio monetario refleja la importancia creciente de la investigación básica biomédica, y sigue con el reconocimiento continuado de Johnson & Johnson de la excelencia en este campo.

El Dr. Paul Janssen Award for Biomedical Research honora al doctor Paul Janssen (1926-2003), ampliamente reconocido como uno de los científicos más productivos del Siglo XX. Conocido en la comunidad científica como el "doctor Paul", Janssen fue responsable de innovadores tratamientos en áreas de enfermedades como el tratamiento del dolor, psiquiatría, enfermedades infecciosas y gastroentereología, fundando Janssen Pharmaceutica, N.V., una compañía de Johnson & Johnson.

"La ciencia innovadora y tecnología cuentan con el poder de transformar el mundo", explicó Paul Stoffels, médico, responsable científico y presidente mundial farmacéutico de Johnson & Johnson. "A través del Dr. Paul Janssen Award for Biomedical Research, Johnson & Johnson honora al legado inspiracional del doctor Paul y aplaude a los investigadores de hoy cuyos descubrimientos cuentan con el potencial para transformar el futuro de la salud humana".

En 2014, el premio fue presentado a las doctoras Emmanuelle Charpentier y Jennifer Doudna, cuya colaboración ha llevado al descubrimiento de un nuevo método para manipular de forma precisa la información genética en las formas que debería producir nuevas visiones en la salud y enfermedad, y podría llevar al descubrimiento de nuevos objetivos para el desarrollo de fármacos. Las doctoras Charpentier y Doudna ganaron el 2015 Breakthrough Prize in Life Sciences. Otros de los premiados al 2015 Breakthrough Prize in Life Sciences incluyeron a los doctores Victor Ambros y Gary Ruvkun, ganadores del 2012 Dr. Paul Janssen Award.

"Como en los últimos años, estamos impacientes por seleccionar al ganador(es) del 2015 Dr. Paul Janssen Award entre los nominados de personas valiosas de instituciones de investigación y compañías de todo el mundo, cuya investigación ha mejorado de forma importante la salud humana", comentó Craig Mello, Ph.D. del Howard Hughes Medical Institute Investigator y profesor del Programa de Medicina Molecular de la University of Massachusetts Medical School y presidente del 2015 Dr. Paul Janssen Award Selection Committee.

Los anteriores ganadores del premio incluyen a David Julius, Ph.D. de la University of California San Francisco; Victor Ambros, Ph.D. de la University of Massachusetts Medical School; Gary Ruvkun, Ph.D. del Massachusetts General Hospital and Harvard Medical School; Napoleone Ferrara, M.D. Del Genentech Fellow; Anthony S. Fauci, M.D. y director del National Institute of Allergy and Infectious Diseases (NIAID); Erik De Clercq, M.D., Ph.D. y presidente del Department of Microbiology and Immunology de la Medical School de la Catholic University of Leuven; Axel Ullrich, Ph.D. y director del Department of Molecular Biology, Max Planck Institute of Biochemistry en Alemania; Profesor Marc Feldmann, FMedSci, FAA, FRS y profesor emérito de Sir Ravinder Maini, FRCP, FMedSci, FRS del Kennedy Institute of Rheumatology del Imperial College London; y Craig Mello, Ph.D. y Premio Nobel del Howard Hughes Medical Institute y de la University of Massachusetts Medical School.

El ganador del 2015 Dr. Paul Janssen Award se anunciará en la primavera de 2015.

Acerca del Dr. Paul Janssen Award for Biomedical Research
Creado por Johnson & Johnson, el Dr. Paul Janssen Award saluda a los científicos más apasionados y creativos en la investigación clínica y básica cuyos logros científicos han conseguido, o tienen un gran potencial para conseguir, un impacto ponderable en la salud humana. El Dr. Paul Janssen Award debe su nombre al doctor Paul Janssen, fundador de Janssen Pharmaceutica, N.V. en 1953. Conocido por sus colegas como "doctor Paul", Janssen fue uno de los investigadores más premiados y apasionados del Siglo XX, un científico y físico que ayudó a salvar millones de vidas por medio de su contribución al descubrimiento y desarrollo de más de 80 medicamentos, cuatro de ellos aún en activo en la lista de medicamentos esenciales de la World Health Organization. En 1961, Janssen Pharmaceutica, N.V. Se unió a Johnson & Johnson Family of Companies. El legado Janssen sigue inspirando a Johnson & Johnson y su compromiso de descubrir curas innovadoras para las necesidades médicas no cumplidas. Visite www.pauljanssenaward.com si desea más información.

Acerca de Johnson & Johnson
Cuidar a las personas del mundo a la vez, inspira y une a las personas que trabajan en Johnson & Johnson (NYSE: JNJ). Impulsamos la investigación y la ciencia, aportamos ideas, productos y servicios innovadores que promueven la salud y el bienestar de las personas. Nuestros alrededor de 126.500 empleados en más de 250 empresas operativas de Johnson & Johnson trabajan con socios en el sector de la salud para influir en la vida de más de mil millones de personas todos los días, en todo el mundo.

Contactos de prensa:

Seema Kumar
+1-908-405-1144 (M)
[email protected] 

Diane Pressman
+1-908-927-6171 (O)
[email protected] 

Frederik Wittock
+32-14-60-57-24 (O)
[email protected]  

Related Links

http://www.pauljanssenaward.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment...

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.